Jincy Sajan, APRN
Gerontology · Houston, TXNPI 1710644851
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.4%. Reporting peaked in 2024 at $2,611 and has fallen 85.2% since, to $386 in 2025. Among gerontology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $51.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals AS$1K
- Merck$1K
- Seagen Inc.$347
- Amgen$338
- E.r. Squibb & Sons, L.L.C.$241
- Janssen Scientific Affairs, LLC$222
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,82133%
- Food & beverage$3,19757%
- Education$57410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals AS | 4 | $1,251 |
| Merck | 10 | $1,174 |
| Seagen Inc. | 6 | $347 |
| Amgen | 9 | $338 |
| E.r. Squibb & Sons, L.L.C. | 3 | $241 |
| Janssen Scientific Affairs, LLC | 2 | $222 |
| Lilly USA, LLC | 6 | $209 |
| Incyte Corporation | 5 | $171 |
| Sumitomo Pharma America, Inc. | 10 | $167 |
| AstraZeneca(2 entities) | 4 | $160 |
| Johnson & Johnson | 3 | $154 |
| CTI Biopharma Corp. | 2 | $137 |
| Novartis | 6 | $120 |
| Novo Nordisk | 5 | $115 |
| Rigel Pharmaceuticals, Inc. | 2 | $92 |
| 180 Medical, Inc. | 4 | $90 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $82 |
| GSK | 3 | $77 |
| Bristol Myers Squibb | 4 | $72 |
| AbbVie | 3 | $50 |
| Boehringer Ingelheim | 1 | $31 |
| Pfizer | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Procept Biorobotics Corporation | 1 | $27 |
| Laborie Medical Technologies Corp. | 2 | $25 |
| Eisai Inc. | 1 | $25 |
| Deciphera Pharmaceuticals Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Morphosys, US Inc. | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,592 in reported general payments places this provider in the 90th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 12 | $7,259 |
| Tamsulosin Hcl | 38 | $731 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $205 |
| Finasteride | 13 | $136 |
| Ciprofloxacin Hcl | 33 | $131 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $55 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $18 |
| Diazepam | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $16 | $7,25912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 gerontology providers in Texas.
Other gerontology in Houston
- Scott ZelaHouston$28K
- Meagan ChavarriaHouston$21K
- Kellie MyersHouston$13K
- Derek SmithHouston$9K
- Krystal ShiloHouston$8K
- Irene KyritsisHouston$8K
- Emily BennettHouston$7K
- Norah OwinoHouston$6K
- Katherine GraapHouston$5K
- Jennifer ReedHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.